PDF
ePub
Citation
Print
Abstract
Background
Anemia is quite common in lung cancer patients and known to decrease the quality of life. Darbepoetin alfa is an erythropoiesis-stimulating protein approved for administration to cancer patients. This study examined the efficacy and safety of darbepoetin alfa in lung cancer patients with a hemoglobin concentration <10 g/dl during chemotherapy.
Methods
Lung cancer patients (n=178) received darbepoetin alfa at doses of 1.91 µg/kg per week until the hemoglobin concentration increased to >10 g/dl. The efficacy and safety were measured by comparing the hemoglobin concentration and assessing the adverse events.
Results
After chemotherapy, the hemoglobin concentration decreased to 9.03±0.64 g/dl. With the darbepoetin alfa treatment, the hemoglobin concentration increased to 10.09±1.17 g/dl after 4 weeks reaching a peak hemoglobin concentration of 10.45±1.18 g/dl. The changes in hemoglobin after 4 and 8 weeks with treatment were 1.08±1.24 g/dl and 1.38±1.59 g/dl (p<0.01). At least a 1 g/dl or more increase in hemoglobin was observed in 62.4% of patients. There were no serious adverse effects except for some mild reactions.
Figures and Tables
Figure 1
Change of hemoglobin concentration before and after administrations of darbepoetin alfa. Darbepoetin alfa administered every 1 week significantly increased mean hemoglobin levels in chemotherapy induced anemia. Increased hemoglobin levels after administration of darbepoetin alfa were shown over the course of the study period.
Figure 2
The comparison of hemoglobin concentration changes between darbepoetin alfa responders and non-responders. The hemoglobin levels were significantly different between responders and non-responders after darbepoetin alfa administration. Also non-responders at 2 weeks have no change of hemoglobin levels at 4 weeks.
References
1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999. 91:1616–1634.
2. Scagliotti GV, Novello S. Role of erythropoietin in the treatment of lung cancer associated anaemia. Lung Cancer. 2001. 34:Suppl 4. S91–S94.
3. Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health. 2005. 8:149–156.
4. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts--blood conservation. N Engl J Med. 1999. 340:525–533.
5. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001. 19:2875–2882.
6. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998. 16:3412–3425.
7. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003. 21:366–373.
8. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004. 15:979–986.
9. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics. 2005. 23:505–514.
10. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist. 2004. 9:451–458.
11. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist. 2005. 10:642–650.
12. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoe tin alfa)]. Information for Healthcare Professionals [Internet]. 2007. 02. 16. cited 2007 Mar 21. Silver Spring: U.S. Food and Drug Administration/Center for Drug Evaluation and Research;Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm.
13. Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer. 2005. 6:446–454.
14. Aranesp (darbepoetin alfa) [package insert]. 2008. 03. Thousand oaks, CA: Amgen Inc..
15. Procrit (epoetin alfa) [package insert]. 2008. 03. Raritan, NJ: OrthoBiotech. L.P..
16. Lastiri JM, Specterman SR, Rendo P, Pallotta MG, Varela MS, Goldstein S. Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer. Medicina (B Aires). 2002. 62:41–47.
17. Rodgers GM. Clinical practice guidelines in oncology: cancer and treatment-related anemia [Internet]. 2005. cited 2005 Dec 10. Fort Washington: National Comprehensive Cancer Network;Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
XML Download